Bioinvent International Ab · OMXSTO:BINV
Bioinvent International Ab — Shareholder Meeting (May 2024)
17 slides from Bioinvent International Ab's shareholder meeting presentation, May 3, 2024
Slide 1: Unleashing Immunity to Fight Cancer
UNLEASHING IMMUNITY TO FIGHT CANCER Annual General Meeting Martin Welschof, CEO May 3, 2024
Slide 2: Forward-Looking Statement
FORWARD-LOOKING STATEMENT This presentation does not constitute or form part of any offer or invitation to purchase or subscribe for, or any offer to underwrite or otherwise acquire, any shares or any other securities in BioInvent International AB (“BioInvent”). Neither shall the presentation or any
Slide 3: BioInvent is focused on novel treatments of cancer
BIOINVENT IS FOCUSED ON NOVEL TREATMENTS OF CANCER In brief 6 Clinical programs Six expanding clinical programs. Integrated research engine, functional screening and in-house GMP manufacturing. Translating complex cancer biology 10+ Partnership agreements Technology validating deals with Exelixis, P
Slide 4: Our success factors
OUR SUCCESS FACTORS Success factors BioInvent has one of the most exciting and unique cancer immunotherapy pipelines of any European biotech company DISCOVERY ENGINE TOP EXPERTISE INNOVATIVE R&D Our proprietary high-quality antibody Everything we do is based on our We have integrated drug developmen
Slide 5: Using partnerships to validate our capabilities and expertise
USING PARTNERSHIPS TO VALIDATE OUR CAPABILITIES AND EXPERTISE Partners Exclusive license agreement and clinical collaboration for BI-1206 for China/Hong Kong/Macau/Taiwan Co-developing (50/50 share of costs and profits) of oncolytic virus BT-001 for solid tumors, leveraging BioInvent’s n-CoDeR® and
Slide 6: Looking back at an eventful 2023
BioInvent presents positive first clinical data on LOOKING BACK AT AN EVENTFUL 2023 anti-FcyRIIB antibody BI-1607 BioInvent enrolls first patient in Phase 1/2a clinical trial with TNFR2 antibody BI-1910 BioInvent presents positive data at SITC from clinical Phase 1/2a trial of BI-1808 as single agen
Slide 7: Strong proprietary clinical pipeline with multiple value drivers
STRONG PROPRIETARY CLINICAL PIPELINE WITH MULTIPLE VALUE DRIVERS Clinical pipeline 1 1 2 1 Licensed to CASI for China, Hong Kong, Macau and Taiwan 2 50/50 co-development collaboration with Transgene 7 │
Slide 8: BI-1808 positive single agent phase data
BI-1808 POSITIVE SINGLE AGENT PHASE 1 DATA TNFR2 BI-1808 Robust partial response (PR) observed in a patient with GIST Phase 1 data presented at SITC Nov 2023 • All subjects had advanced solid tumors (21 evaluable) • Heavily pretreated patient population, tumor types known to respond poorly to checkp
Slide 9: BI-1910: potential best-in-class targeting an identified unmet need
BI-1910: POTENTIAL BEST-IN-CLASS TARGETING AN IDENTFIED UNMET NEED TNFR2 BI-1910 A differentiated, agonist approach to treating solid tumors compared to BI-1808 • Enrolment ongoing in Phase 1/2a clinical trial in the US and Europe since December 2023 • Innovative, adaptive clinical trial design for
Slide 10: BI-1206 in NHL: impressive early clinical efficacy data
FcyRIIB BI-1206 IN NHL: IMPRESSIVE EARLY CLINICAL EFFICACY DATA BI-1206 + ritux Quality of responses particularly impressive 3 PARTIAL Interim results from IV RESPONSES (June 2023): • 4 Complete Responses (CR), 3 Partial Responses (PR) and 4 Long-lasting cases of stable disease (SD) • CR:s have been
Slide 11: BI-1206 in NHL: positive interim clinical efficacy data from study in China
BI-1206 IN NHL: FcyRIIB BI-1206 + POSITIVE INTERIM CLINICAL EFFICACY DATA FROM STUDY IN CHINA ritux CASI Phase 1 dose- escalation data re-inforce previously reported 4 positive efficacy data PARTIAL (March 2024): RESPONSES Durable • 1 Complete Responses (CR), 4 Partial Responses (PR) out of 8 evalua
Slide 12: BI-1206 in NHL: agreement with AstraZeneca
FcyRIIB BI-1206 IN NHL: AGREEMENT WITH ASTRAZENECA BI-1206 triplet BI-1206 in combination with rituximab and Calquence • AstraZeneca to provide Calquence (BTK inhibitor) for combination with BI-1206 and rituximab in the ongoing Phase 1/2a clinical study for the treatment of patients with follicular
Slide 13: BI-1206 in solid tumors: positive interim clinical phase 1 results
FcyRIIB BI-1206 IN SOLID TUMORS: POSITIVE INTERIM CLINICAL PHASE 1 RESULTS BI-1206 + pembro Early signs of efficacy in BI-1206 IV + pembrolizumab Phase 1 (June 2023): • All patients enrolled had received at least one prior line of anti- PD1/PDL1 therapy • 18 evaluable patients in IV arm (6/2023) • N
Slide 14: BI-1607: positive clinical phase data
BI-1607: POSITIVE CLINICAL PHASE 1 DATA FcyRIIB BI-1607 Well-tolerated and stable disease in 6/11 patients Phase 1 data of BI-1607 in combination with trastuzumab were presented at the San Antonio Breast Cancer Symposium in Dec 2023. • Treatment well-tolerated, no serious adverse events related to B
Slide 15: BT-001: single agent phase data opens for combination
BT-001: SINGLE AGENT PHASE 1 DATA OPENS FOR COMBINATION CTLA-4 BT-001 Objective antitumor activity, i.e. decrease of injected lesion size of ≥50% observed in two patients Data from Phase 1/2a open-label, multicenter, dose-escalation study of BT-001 as single agent • Treatment of all Phase 1 cohorts
Slide 16: Expected key clinical milestones 2024
EXPECTED KEY CLINICAL MILESTONES 2024 YE 2024 H1/mid-2024 H2/YE 2024 16 │
Slide 17: www.bioinvent.com
www.bioinvent.com Follow us
BioInvent International — Shareholder Meeting (May 2024) on 6ix